Discover and read the best of Twitter Threads about #standardcare
Most recents (1)
Apropos the debate about @BioconLimited's limited trial of its #Itoluzimab, this is a brief note (that might grow) about common misunderstandings of terms and concepts in the statistical theory that underpins clinical trials and indeed statistics in general
So here goes:
So here goes:
1. The p- value that is often quoted in papers and journal articles and in the case of #Itoluzimab even in press conferences. It is NOT the probability that the results arose by chance. That is almost a nonsense statement. The results observed are the results.
If the null hypothesis was true-that there was indeed no difference (in the wider population of patients) between #Itoluzimab and #standardcare, THEN the probability that we would have observed in our trial of 30 patients a difference this big or bigger - that is the p value.
